Effect of atorvastatin on cognitive functions in patients with chronic brain ischemia and metabolic syndrome
- 1State Institution «Institute of Gerontology name D.F. Chebotarev NAMS of Ukraine», Kyiv
- 2State Institution "Institute of Gerontology them. DF Chebotarev NAMS of Ukraine "Kyiv
Summary. The aim of the study was to assess the cognitive function in patients with chronic brain ischemia and metabolic syndrome (MC ) during the treatment of hyperlipidemia with atorvastatin. We examined 300 patients with dyscirculatory encephalopathy (DE) and MS aged 48–85 years. All patients were assigned into two groups: main — atorvastatin users (n=113; of which 40 were in middle age, 61 — in old age, 12 — senile) and the control group — non-users of any statin (n=187, of which 63 were in middle age, 104 — in old age, 20 — senile). Mini Mental State Examination (MMSE) and other neuropsychological tests were used to assess the cognitive functions of patients. According to the results of the MMSE and other neuropsychological tests, there was no statistically significant difference in cognitive status and severity of the cognitive impairment between patients of main and control groups. The positive correlation was found between the duration of atorvastatin intake and MMSE total score in patients with DE and MC, that could mean a positive effect of longer atorvastatin therapy on cognitive functions. When the data of different age groups was analyzed separately, it was detected the significant correlation between the duration of atorvastatin intake and MMSE total score only in old age patients with DE and MC, but not in middle age and senile patients. Key words: cognitive functions, treatment with atorvastatin, metabolic syndrome.
Full text is available in Russian.